Lunai Bioworks, Inc. (NASDAQ: LNAI) ("Lunai"), an AI-driven drug discovery company, and Geneial, Inc., a precision medicine data infrastructure and patient engagement company, today announced that BioSymetrics, a wholly owned Lunai subsidiary, has signed a Letter of Intent (LOI) with Geneial to pursue a strategic collaboration in rare neurological disorders.


The collaboration is designed to support rare disease research and advocacy groups in converting fragmented, patient-generated data into actionable drug development programs, including the creation and activation of trial-ready patient cohorts that can support pharmaceutical partnerships.

Initial programs are expected to integrate datasets across multiple patient registries, incorporating longitudinal clinical data to support cohort development and translational research across indications.